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Abstract 
The calcitonin/calcitonin gene-related peptide (CGRP) family of peptides includes calcitonin, 
 and  CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD). 
Their receptors consist of one of two G protein-coupled receptors (GPCRs), the calcitonin 
receptor (CTR) or the calcitonin receptor-like receptor (CLR). Further diversity arises from 
heterodimerisation of these GPCRs with one of three receptor activity-modifying proteins 
(RAMPs). This gives the CGRP receptor (CLR/RAMP1), the AM1 and AM2 receptors 
(CLR/RAMP2 or RAMP3) and the AMY1, AMY2 and AMY3 receptors (CTR/RAMPs1-3 
complexes, respectively). Apart from the CGRP receptor, there are only peptide antagonists 
widely available for these receptors and these have limited selectivity, thus defining the 
function of each receptor in vivo remains challenging. Further challenges arise from the 
probable co-expression of CTR with the CTR/RAMP complexes and species-dependent splice 
variants of the CTR (CT(a) and CT(b)). Furthermore, the AMY1(a) receptor is activated equally 
well by both amylin and CGRP and the preferred receptor for AM2/IMD has been unclear. 
However, there are clear therapeutic rationales for developing agents against the various 
receptors for these peptides. For example many agents targeting the CGRP system are in 
clinical trials and pramlintide, an amylin analogue, is an approved therapy for insulin-requiring 
diabetes. This review provides an update on the pharmacology of the calcitonin family of 
peptides by members of the corresponding subcommittee of the International Union of Basic 
and Clinical Pharmacology and colleagues. 
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1. Introduction to the family, their receptors and current classification 
The peptides calcitonin (CT), calcitonin gene-related peptide (CGRP), amylin, adrenomedullin 
(AM), and adrenomedullin 2/intermedin (AM2/IMD) form a family of related peptides (Figure 
1). CGRP exists in two forms, CGRP and CGRP; in some species, CGRP is not found but 
another peptide, CT receptor stimulating peptide (CRSP) is found instead (Katafuchi et al., 
2009). There has been considerable expansion of the family in fish, such that there are two 
forms of CT and 5 forms of AM (Watkins et al., 2013).  
 
The peptides themselves, whilst showing only limited sequence homology, are related 
structurally by possession of a disulphide-bonded N-terminus, a region with strong alpha-
helical tendencies and a C-terminus structured around a beta-turn and a C-terminal amide. The 
peptides range in length from 32 (CT) to 52/53 amino acids (AM, AM2/IMD). In the latter two 
peptides, the first residues N-terminal to the disulphide bond do not appear to be necessary for 
biological activity and the AM and AM2/IMD peptides can be considered as functional ~40 
amino acid peptides (Bower and Hay., 2016, Watkins et al., 2013, Hong et al., 2012, Bailey 
and Hay 2006). 
 
The peptides have a range of biological activities. CT, the first to be discovered, is a hormone 
produced by C cells of the thyroid, whose role is to reduce plasma calcium and promote bone 
formation (Findlay and Sexton, 2004), although CT-deficient mice show a paradoxical 
inhibition of bone formation due to enhanced sphingosine-1-phosphate production (Keller et 
al., 2014). Amylin is produced by the pancreas and functions as a satiety hormone, regulating 
nutrient intake but may also have other roles as recently reviewed (Hay et al., 2015). CGRP 
and AM are both potent vasodilators (Russell et al., 2014, Hinson et al., 2000). CGRP is a 
neuromodulator found in sensory neurons; it plays an important role in neurogenic 
inflammation (i.e where sensory nerves release mediators that promote inflammation); in this 
case CGRP causes vasodilation and promotes fluid exudation from blood vessels. AM is 
chiefly found in endothelial cells; it is important both in vascular homeostasis and also 
angiogenesis and lymphangiogenesis. AM2/IMD is also found in vascular endothelial cells and 
probably has complementary roles to AM, although much about this peptide remains unclear. 
Each peptide appears to have both peripheral and central actions, though due to the complexity 
of this peptide-receptor system, it is not yet clear which effects are physiological versus 
pharmacological or which receptors are responsible for many effects. 
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The peptides all act at class B G protein coupled receptors (GPCRs). There are seven distinct 
receptors for the peptides in mammals (excluding splice variants), but only two GPCRs; the 
CT receptor (CTR) and CT receptor-like receptor (CLR, known as CL or CRLR in older 
literature). The additional functional receptors arise from the association of CTR or CLR with 
receptor activity-modifying proteins (RAMPs) (McLatchie et al., 1998). There are three 
RAMPs. These each have an N-terminus of around 100-120 amino acids, a single 
transmembrane domain and a C-terminus of around 10 residues (Hay and Pioszak, 2016). The 
receptors are shown in Figure 2. 
 
Like other class B GPCRs, activation of CLR and CTR follows the two-domain model, where 
this is achieved by binding of the C-terminus of the peptide to the extracellular domain (ECD) 
of the receptor, contributing to the overall affinity of the peptide. The peptide N-terminus binds 
to the transmembrane domain (TMD) of the receptor. The receptors for the CT/CGRP family 
preferentially signal through Gs and cAMP production, although other signal transduction 
pathways may be activated (Walker et al., 2010). As further work characterising the signalling 
of these receptors emerges, it will be important to consider how the pharmacology of these 
receptors compares at different signalling pathways.  
 
The current scheme for receptor classification may be found on the IUPHAR/BPS Guide to 
Pharmacology website (http://www.guidetopharmacology.org/) at 
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=11, and is 
shown in Figure 2. This is reviewed each year and is fully annotated with current references 
(Hay and Poyner 2017, Alexander et al., 2015). Readers are referred to this for details of 
classification and also for information on receptor distribution. These pages mainly consider 
human receptors and so this information may not automatically apply to other species, where 
there are frequently differences in pharmacology. The structure-function relationships of 
RAMPs, CGRP and amylin have been recently considered elsewhere (Bower and Hay, 2016, 
Watkins et al., 2013, Hay and Pioszak, 2016), as has the clinical pharmacology of CGRP 
antagonists and antibodies (Karsan and Goadsby, 2015, Hou et al., 2017, Tso and Goadsby, 
2017). In this review, the intention is to explore areas where there are significant gaps in our 
understanding, to guide research in this field. 
 
2. Pharmacology 
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The current classification of the seven receptors is based on work done shortly after the 
discovery of the RAMP family (McLatchie et al., 1998, Christopoulos et al., 1999, Muff et al., 
1999). The CLR by itself will not reach the cell surface in any significant amount and does not 
respond to any known ligand. With RAMP1 it becomes the CGRP receptor (i.e. CLR/RAMP1). 
Association with the other two RAMPs gives AM receptors; the AM1 receptor with RAMP2 
(CLR/RAMP2) and the AM2 receptor with RAMP3 (CLR/RAMP3) (Figure 2, Figure 3). 
AM2/IMD shows a preference for the AM2 receptor; this is discussed further below.  
 
The CTR, by itself, preferentially responds to CT. The CTR can also associate with the three 
RAMPs to give AMY1, AMY2 and AMY3 receptors (Figure 2). As their names suggest, these 
respond to amylin (Hay et al., 2015; Poyner et al., 2002). There are however a number of 
important extra considerations. The CTR exists as a number of splice variants and these are 
species dependent. The most significant of these for the human receptor are the absence (CT(a)) 
or presence (CT(b)) of a 16 amino acid insert in the first intracellular loop; this impairs coupling 
of the CTR to Gq whilst making little difference to Gs coupling. Thus in turn gives (a) and (b) 
subtypes of each of the AMY receptors (Moore et al., 1995, Poyner et al., 2002). Secondly, the 
CTR can express at the cell surface on its own so in transient expression systems, it is highly 
likely that there will be mixed populations of CTR/RAMP complexes and CTR alone. This 
makes it very difficult to interpret the action of CT at AMY receptors in functional assays, as 
CT will produce a strong cAMP response via the CTR that is inevitably present. This is 
illustrated in Figure 4 at the AMY1(a) and AMY3(a) receptor transfected into Cos7 cells (Hay et 
al., 2005). At both of these receptors CT fails to displace 125I-amylin indicating that CT and 
amylin do not share a common receptor (Figure 4A and B). However, at both receptors CT 
stimulates a potent cAMP response (Figure 4C and D). This disconnect between binding and 
function could be explained by the presence of free CTR in these cells. The complex between 
CTR and RAMP2 is particularly difficult to observe, and depends on the cell type used, and so 
the pharmacology of this receptor is poorly explored.  
 
Many class B GPCRs form heterodimers. This does not seem to have been addressed in any 
published study for CTR or CLR. For CLR the requirement for a RAMP may mitigate against 
this. For CTR, homodimerisation is well described (Harikumar et al., 2010); the main ligand 
responsive species may be a dimer, with G protein binding causing monomer formation 
(Furness et al., 2016). 
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For most receptors, the main pharmacological tools for their characterisation are the peptide 
agonists themselves and N-terminally truncated peptides that usually act as antagonists. For 
some combinations of peptides and receptors there is reasonable selectivity; thus at the AM 
receptors there is a preference for AM over CGRP for ligand binding and cAMP production 
(Figure 3). However, over the entire family it is difficult to use these agents to fully distinguish 
between receptors (Bailey and Hay, 2006, Hay et al., 2005). For CLR-based receptors, non-
peptide antagonists are also available (Salvatore et al., 2006); those of the “gepant” class bind 
to the receptor ECD at the interface between RAMP1 and CLR and have better selectivity than 
peptide antagonists (Moore and Salvatore, 2012), although they still need to be used with care 
as they can also block AMY1 receptors (Walker et al., 2017, Hay and Walker, 2017). 
 
2.1 Heterogeneity in CGRP-responsive receptors 
The early literature on CGRP receptors was dominated by discussion of heterogeneity. Many 
responses could be antagonised by CGRP8-37, with a pA2 of about 8 on human and rat cells. By 
contrast, in a number of model systems, typified by the rat vas deferens, CGRP agonism is 
relatively resistant to CGRP8-37. It was suggested that CGRP was acting via another receptor; 
the CGRP2 receptor. Molecular cloning demonstrated that the “CGRP1” receptor corresponds 
to the CLR/RAMP1 complex and it has been suggested that the “CGRP2” receptor represented 
the action of CGRP at the various AM and AMY receptors (Hay et al., 2008). The high potency 
of CGRP in functional (cAMP) and binding assays at the AMY1(a) receptor and the AMY1(b) 
receptor was noted in previous studies (Udawela et al., 2008, Tilakaratne et al., 2000, Hay and 
Walker, 2017, Hay et al., 2006, Leuthauser et al., 2000). More recent work has confirmed that 
the AMY1(a) receptor can respond as well to CGRP as it does to amylin (Walker et al., 2017, 
Walker et al., 2015, Hay and Walker, 2017) (Figure 5). Even more importantly, there is 
evidence that in vivo, CGRP may exert effects by activating AMY1 receptors. This has 
potentially important implications for understanding CGRP biology and for using antagonists; 
it may be necessary to use agents that block both CLR/RAMP1 and CTR/RAMP1 to fully 
antagonise the effects of CGRP in vivo (Walker et al., 2015). Where high concentrations of 
non-peptide antagonists are used, this may already be the case because these show only limited 
selectivity between CGRP and AMY1 receptors (Hay and Walker, 2017). 
 
The classification of CLR/RAMP1 as the CGRP receptor does not rule out the possibility of 
other endogenous CGRP receptors, such as AMY1. The ongoing interest in the CGRP system 
as a drug target in migraine makes it especially important to remember the early reports of 
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functional heterogeneity which in many cases still do not have a molecular correlate (Hay et 
al., 2008). Perhaps unfortunately, the name AMY1, does not easily lend itself to an obvious 
role in CGRP biology. The dual activation of this receptor by both CGRP and amylin creates 
problems for nomenclature. There is insufficient information regarding the location and 
function of this receptor in vivo either as a CGRP or amylin receptor at the present time. 
Readers are urged to consider this receptor both in amylin and CGRP biology to assist with 
refining receptor nomenclature. 
 
2.2 Endogenous agonists 
2.2.1 AM2/IMD 
AM2/IMD remains poorly understood. It has a wide range of effects on the cardiovascular 
system, adipose tissue and macrophages and the kidney. It increases prolactin release and in 
the CNS it reduces food intake and causes activation of the sympathetic nervous system (Zhang 
et al., 2017, Hong et al., 2012). It is sometimes reported to be more potent in vivo than AM and 
the distribution of its mRNA is distinct from that of AM, being preferentially expressed in the 
thyroid and kidney, compared to the placenta and adipocytes where AM mRNA is most highly 
expressed (Figure 6). When reviewing the current data at human CLR-based receptors, 
AM2/IMD appears to be most potent at the AM2 receptor (Figures 3 and Figure 7), being 
equipotent to AM at this receptor. Equal potency for AM and AM2/IMD at the AM2 receptor 
has also been reported for rat and mouse receptors (Halim and Hay, 2012). This profile is 
different to the AM1 receptor where AM has higher potency than AM2/IMD (Figures 3 and 7), 
however these data are only available for cloned human receptors. AM2/IMD can also activate 
CTR and AMY receptors but there is much less data. When comparing data between species, 
the activity of AM2/IMD may be greater at rat AMY3(a) receptors, compared to the human 
receptor but this needs more investigation (Bailey et al., 2012, Hay et al., 2005). However, the 
pattern appears similar to the situation with AM, which may also have more activity at rat, 
compared to human AMY3(a) receptors (Bailey et al., 2012). It has been suggested that a distinct 
receptor for AM2/IMD may exist (Hashimoto et al., 2007; Taylor et al., 2006). Given its 
affinity at several CLR and CTR-based receptor complexes, we consider this to be unlikely and 
that one or more existing complexes are likely to mediate the effects of this peptide, although 
we acknowledge that some results in the literature are difficult to explain (Taylor et al., 2006). 
The lack of useful antagonists makes this a continuing problem. Furthermore, signalling bias 
has been little explored at these receptors and it is unclear what distinctive features may come 
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from AM/IMD activating each of the individual receptors. Thus the pharmacology and 
physiology of AM2/IMD remain somewhat elusive. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
The actions of AM2/IMD are further complicated due to its metabolism, where it can 
potentially exist in a number of N-truncated forms, all of which retain the key disulphide bond 
which is considered essential for full activity. It remains far from clear what the most 
physiologically important form of the peptide is and what are the implications of the potential 
metabolism for its activity (Hong et al., 2012, Zhang et al., 2017). Another AM, AM5 has also 
been reported in some mammals but its actions are not well understood (Takei et al., 2008). 
 
2.2.2 CGRP and CRSP 
CGRP is encoded by a different gene to CGRP and has a different pattern of expression, 
being particularly prominent in the enteric nervous system. This has led to the view that CGRP 
has restricted expression but this is not necessarily the case, and is found throughout the CNS 
(Amara et al., 1985). It is found in only a small number of species, chiefly rodents and primates. 
The differences between the forms are species-dependent (Figure 1). In rat CGRP, there are 
two differences at positions 17 and 35, compared to rat CGRP. In humans, there are three 
differences, at positions 3, 22 and 25. There are suggestions of subtle differences in receptor 
activity of human and rat  and  CGRP, although this has not been explored in any detail 
(Bailey and Hay, 2006, Bailey et al., 2012). In other species (but not humans), a second CGRP-
like peptide named CRSP is expressed. There is an interesting paradox with this peptide. Its 
sequence clearly marks it as a CGRP variant (Figure 1); however, it is reported to activate 
CTR-based receptors and to have very little activity on CLR-based receptors, including the 
CGRP receptor (Katafuchi et al., 2009, Katafuchi et al., 2004, Katafuchi and Minamino, 2004, 
Katafuchi et al., 2003). The reason for this is not known and this peptide would benefit from 
further study. However, matching sequence to pharmacology for these peptides and complex 
receptors is not an easy task. CGRP and amylin are the most closely related of the CT family 
of peptides in mammals, yet CGRP activates CTR and CLR-based receptors with RAMP1, 
whereas amylin is much more selective for CTR/RAMP complexes. The nature of the C 
terminal amino acid seems like a good place to look to explain this, with Phe37 in CGRP and 
Tyr37 in amylin, yet AM shares a C-terminal Tyr with amylin but has a strong preference for 
CLR/RAMP complexes.  
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3. Developments with agonists 
Recent attention has focussed on the development of metabolically stable peptide agonists 
because the members of this peptide family can be metabolised by a range of peptidases and 
have several cleavage sites (Kim et al., 2013, Schonauer et al., 2016). For CGRP, a fatty acid 
attached to a serine at position 1 of human CGRP gives an analogue with markedly prolonged 
in vivo biological activity (Nilsson et al., 2016). AM has been modified by palmitoylation, 
lactam cyclisation and N-methylation to produce an analogue with prolonged half-life 
(Schonauer et al., 2016). For pramlinitide, a non-aggregating analogue of human amylin, 
glycosylation has been used as an approach to enhance stability (Yule et al., 2016, Kowalczyk 
et al., 2014, Tomabechi et al., 2013). The key to these peptide mimetic development 
programmes is the identification of sites on the peptide that allow derivatisation without 
compromising either receptor binding or activation. In principle, this will be facilitated by the 
availability of structures showing the peptides bound to their cognate, full-length receptors, 
although the difficulty of predicting where an elongated substituent such as a fatty acid might 
bind should not be underestimated. In principle, similar problems might be anticipated in the 
preparation of other derivatives such as fluorescent peptides (Cottrell et al., 2005) where their 
use at relatively high concentrations may be needed to counter reduced affinity. The activity of 
analogues is usually only tested against cAMP production, leaving open the formal possibility 
that they have altered signalling bias. 
 
Salmon CT has historically been used to treat Paget’s disease and osteoporosis in people 
(Gennari and Agnusdei, 1994). However, due to side effects, relative efficacy compared to 
other treatments and lack of cost effectiveness, its use has declined. Particularly concerning 
was the suggestion that salmon CT may increase the risk of metastases. However, in a recent 
meta-analysis the relationship was described as weak and there is no clear biological 
mechanism (Wells et al., 2016). Given the clinical usage, it is unsurprising that salmon CT has 
been explored in other disorders. Numerous studies have suggested that salmon CT could treat 
metabolic disorders by lowering body weight, elevating energy expenditure, limiting food 
intake and improving glucose handling in rats (Lutz et al., 2000, Eiden et al., 2002, Wielinga 
et al., 2007, Feigh et al., 2012, Feigh et al., 2014). Recently a number of CT mimetics, known 
by “KBP” codes e.g. KBP-042, KBP-088 and KBP-089 have been described (Patent WO 
2015/071229). These molecules are reported to maintain the high efficacy of salmon CT, whilst 
improving tolerability in rats (Gydesen et al., 2017a).  A similar strategy appears to have been 
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employed for the development of Davalintide which displays enhanced effects to reduce body 
weight and food intake compared to amylin in rats (Mack et al., 2010). Development of 
Davalintide has apparently been discontinued. Interestingly, the KBP compounds maintain the 
long-acting ability of salmon CT to stimulate signalling in cell culture models (Gydesen et al., 
2016, Andreassen et al., 2014b). The receptor pharmacology of the KBP peptides has not been 
extensively studied and so far the peptides have only been tested at CTR, AMY3 and CGRP 
receptors (Andreassen et al., 2014a, Gydesen et al., 2016, Gydesen et al., 2017a). They are 
reported to activate both CT and AMY3 receptors but not CGRP receptors, similar to salmon 
CT and are known as “DACRAs” – dual amylin and CT receptor agonists; salmon CT is a 
natural DACRA. Their activity at other AMY receptors has not been tested but close sequence 
similarity to salmon CT of any peptide would make it likely that they show potent agonism at 
all CTR/RAMP complexes. The receptor pharmacology analysis of these peptides has relied 
on purchased stably transfected cell lines, which are not especially well characterised. It is not 
clear how much activity of the ligands occurs via free CTR in this transfected cell system 
(Andreassen et al., 2014a, Gydesen et al., 2017b, Gydesen et al., 2017a, Gydesen et al., 2016). 
As noted above, to determine affinity at a CTR/RAMP complex, displacement of 125I-amylin 
(or 125I-CGRP for the AMY1 receptor) is the most reliable measure of true AMY receptor 
affinity. Further pharmacological characterisation is required to validate the DACRA 
nomenclature and confirm the relative activity of these peptides at different receptor 
complexes.  
 
The future for novel peptides may be to follow the lead for the GLP-1 receptor, where a ligand 
has been designed based on a crystal structure of the receptor (Jazayeri et al., 2017). A number 
of structures are available showing the ECDs of CLR/RAMP complexes or the CTR in complex 
with bound ligands (Table 1, Figure 8). Many of these have been reviewed (Hay and Pioszak, 
2016). In addition, a cryo-electron microscopy structure of the complete CTR bound to Gs and 
CT has been published (Liang et al., 2017), but the ECD and bound ligand in this are poorly 
resolved and are not included in the deposited co-ordinates. Therefore, there is still some way 
to go before there is a complete picture to enable structure-based peptide agonist design for 
these receptors 
 
A series of small molecule agonists for the CTR have been identified and their binding site is 
probably at the junction of the ECD and the transmembrane domain of the receptor (Dong et 
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al., 2009). They probably work allosterically but their pharmacology remains largely 
unexplored. 
 
4. Developments with antagonists 
A major advance in the pharmacology of CGRP receptors came with the “gepant” class of 
antagonists, typified by olcegepant (BIBN4096BS) and telcagepant (MK0974), which were 
developed as part of the global effort to develop drugs that inhibit CGRP action in migraine. 
These compounds have a high selectivity for CGRP as opposed to AM receptors because they 
bind to the interface between CLR and RAMP1. Telcagepant showed therapeutic efficacy in 
migraine and although the development of this particular molecule was halted, non-peptide 
CGRP receptor antagonists continue to be tested in clinical trials. The pharmacology of 
olcegepant and telcagepant has been extensively reviewed previously but a number of 
developments should be noted. Both antagonists showed marked species selectivity in favour 
of primate receptors, restricting their use as experimental tools. Work to develop further 
gepant-type compounds continues (Civiello et al., 2016, Tora et al., 2013, Crowley et al., 
2015). The wider pharmacological characterisation of these compounds has not been 
extensively pursued, but there are some significant exceptions. A study of olcegepant, 
telcagepant, MK-3207 and rimagepant (BMS-927711) on rat mesenteric arteries have shown 
that they all behave as simple competitive antagonists with pA2 values ranging from 8.8 (MK-
3207) to 6.45 (telcagepant). They have similar affinities on mesenteric arteries and in binding 
assays to rat brain apart from rimagepant, which shows a 50-fold lower affinity to brain. The 
reasons for this discrepancy are unclear (Sheykhzade et al., 2017). The selectivity of olcegepant 
and telcagepant for human CGRP and AMY1(a) receptors has been compared at receptors 
transfected into Cos 7 cells. Surprisingly, for olcegepant acting on the AMY1(a) receptor, this 
depends on the pathway being measured; it is 5-fold more potent at blocking CGRP when 
CREB phosphorylation is measured compared to cAMP (Walker et al., 2017). Thus if cAMP 
is measured, olcegepant has over 100-fold selectivity for CGRP over AMY1(a) receptors; for 
CREB this drops to around a 25-fold selectivity. This is not seen to the same extent with 
telcagepant, nor is the differential antagonism observed at the CGRP receptor. The implications 
of this will be considered further below. 
 
The development of the gepant antagonists has tended to draw attention away from other small 
molecule antagonists such as SB-273779 (Aiyar et al., 2001) and other compounds. These 
compounds show little selectivity between CGRP and AM receptors; the binding site for the 
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Merck compounds variously known as compound 4 or compound 16 appears to include part of 
the TMD and extracellular loop (ECL3), well away from the ECD interface between CLR and 
RAMP1 used by the gepants (Salvatore et al., 2006). It is possible that SB-273779 binds in a 
similar place. However, mutagenesis suggests that there are RAMP effects on ECL3 and so it 
may be possible to develop selective antagonists which bind to this region (Watkins et al., 
2016).  
  
There has been work to develop shortened peptide antagonists. A substituted version of the 
final 11 amino acids of CGRP has been reported to bind with a sub-micromolar affinity (Rist 
et al., 1998) and a crystal structure of this bound to the ECD of RAMP1 and CLR has been 
solved (Booe et al., 2015) (Table 1, Figure 8). Chimeras between CGRP8-37, AM22-52 and 
AM2/IMD16-47 produced analogues with novel specificities but whose activities remain 
difficult to understand (Robinson et al., 2009). Homology models of amylin receptors are 
facilitating the development of novel CTR and amylin receptor antagonists, based on the 
related CT family receptor ECD structures (Lee et al., 2016). 
 
A recent development has been the use of antibodies to block the actions of CGRP, as an 
alternative to the use of classic antagonists for the therapy of migraine. The majority of these 
act against CGRP itself (Mason et al., 2017; Tso and Goadsby, 2017), but some success has 
been achieved with antibodies directed to the CGRP receptor, both in experimental models 
(Miller et al., 2016) and human studies (Shi et al., 2016; Tso and Goadsby, 2017).  
 
5. The challenges of pharmacology in non-transfected cell systems 
Whilst studies with transfected cells are essential for defining the pharmacology of individual 
receptor subtypes, they have some limitations. In particular, if pharmacology is influenced by 
cell-specific factors such as G proteins (see below) or accessory proteins, then this will only be 
properly revealed by experiments in the physiologically relevant cell. Even if the receptors are 
identical, differences in responses can be produced by their level of expression and factors such 
as differential expression of peptidases. There are particular considerations where CTR is 
expressed with RAMPs, as it is highly likely that both AMY receptors and free CTR will be 
present at the cell surface. This section provides some examples of pharmacology emerging 
from cells that endogenously express receptors and highlights some of the challenges of using 
“model” cell lines that endogenously express receptor components. 
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5.1. Primary cells 
In cultured rat trigeminal neurons, CTR, CLR and RAMP1 are present, giving a particularly 
complex situation. The data suggest that different cells have either CLR or CTR, sometimes 
with RAMP1 so there are difficulties in comparing functional data of pooled responses to 
individual cells with one or more functional receptors. CGRP-mediated cAMP production is 
blocked by the CT and amylin receptor antagonist AC187 with a pA2 appropriate to the 
AMY1(a) receptor. Antagonism of CGRP responses by olcegepant, however were consistent 
with the presence of the CGRP receptor, CLR/RAMP1, supporting the notion that two 
populations of CGRP-responsive receptors are present in these cells (Walker et al., 2015).  
 
Somewhat similar complexities have been observed with rat embryonic dissociated spinal cord 
cells. In this case, CGRP, AM and AM2/IMD responses have been investigated in two separate 
studies. These cells express high affinity binding sites for both AM and CGRP and both 
peptides also produce cAMP, consistent with the presence of CGRP and AM receptors. A 
selection of antagonists were used to try and define the receptors that mediated cAMP 
responses to each agonist. The response of CGRP was effectively blocked by olcegepant. 
However, the data for AM and AM2/IMD are less straightforward to interpret (Takhshid et al., 
2006). AM2/IMD showed biphasic high and low affinity displacement of bound 125I-AM but 
monophasic high affinity displacement of 125I-CGRP. Despite high affinity for the CGRP 
binding site, antagonism of AM2/IMD by olcegepant was weak, which is not consistent with 
AM2/IMD acting through a canonical CGRP receptor (Owji et al., 2008). It is likely that there 
are mixed populations of receptors, potentially within the same or different cells within these 
cultures, creating mixed pharmacology. It is possible that an amylin receptor could partially 
explain this. Indeed, using the same spinal cell system, amylin responses have also been 
studied. This highlights another mismatch between this endogenous system and transfected 
cells; the potency of amylin8-37. In this study, it achieved a pA2 of 7.94, which is far greater 
than the highest value achieved in transfected cell systems (rat) of 6.16 (Bailey et al., 2012). 
The reason for this is not known. 
 
These few observations serve as examples that reflect the difficulty of working with systems 
that endogenously express one or more populations of receptors. A common problem is that it 
is difficult to test all of the different combinations of agonists and antagonists that are currently 
necessary to tease apart the pharmacology of these receptors. Therefore it is common that 
limited concentrations and ranges of pharmacological tools are used. This is of course a 
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consequence of using cells that are only available in small amounts, and the problem with 
generating very pure cultures. We have used the studies discussed in the preceeding paragraph 
because they are more helpful than many which use only a single concentration of agonist or 
antagonist in an “all or nothing” approach and thus cannot quantify parameters or define 
pharmacology in any meaningful way. For example, if CGRP were to be used in any study of 
rodent tissues or cells at 100 nM or greater concentration, it could potentially act through 
CGRP, AM2, AMY1 or AMY3 receptors. Blockade of this response with 1 µM or greater 
CGRP8-37 would not rule in or out any of these receptors because this concentration of 
antagonist can block all of these receptors. Hence, the concentrations and combinations of 
agents used are very important and further work is needed on ex-vivo cells, to establish the 
pharmacology that they display. Similar issues are often faced in cell lines. 
 
5.2. Cell lines 
Despite the challenges associated with endogenously expressed receptors, the SK-N-MC cell 
line (derived from a human neuroblastoma) has proven invaluable for understanding CGRP 
receptor pharmacology (Poyner et al., 1992). SK-N-MC cells have been extensively 
characterised and display pharmacology consistent with a functional CGRP receptor in 
transfected cells (Bailey and Hay, 2006). These cells have been used as a starting point for the 
pharmacological characterisation for several CGRP receptor antagonists (Moore and Salvatore, 
2012). However, this model is not perfect. They reportedly express RAMP2 in addition to 
CGRP receptor components (CLR and RAMP1) and lose their CGRP receptor phenotype over 
passages (Choksi et al., 2002). Similarly, the human breast cancer cell line, T47D displays 
pharmacology consistent with a CTR and may represent an appropriate model for studying the 
pharmacology of this receptor (Muff et al., 1992, Zimmermann et al., 1997). Thus, SK-N-MC 
and T47D cells appear to be appropriate models to study the pharmacology of CGRP and CT 
receptors respectively. However, it should be noted that the compliment of downstream 
intracellular signalling proteins may be very different between these cell lines and a 
physiological tissue. They may therefore not be suitable for deciphering intricate biological 
activities.  
 
Using a similar rationale other human cell lines including Col 29 (colonic epithelial) and MCF-
7 (breast cancer) have been examined for their responsiveness to CGRP and related peptides 
(Hay et al., 2002, Zimmermann et al., 1997). However the pharmacology reported for these 
cell lines is not straight forward. Despite this, MCF-7 cells have been used in several studies 
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as an amylin receptor model (Sisnande et al., 2015, Shi et al., 2016). These cells are reported 
to express mRNA encoding two distinct splice variants of CTR, RAMP1 and RAMP3 (Chen 
et al., 1997, Ellegaard et al., 2010). MCF-7 cells therefore have the potential to contain 
functional CTR, AMY1 and AMY3 receptors. In these cells, CT stimulated cAMP production 
potently and 125I-CT binding was not displaced by amylin or CGRP, suggesting that the CTR 
may be present. However, the potent cAMP response to amylin, coupled with the weak 
displacement of 125I-amylin binding by CGRP relative to amylin is consistent with the AMY3 
receptor in transfected cell models (Zimmermann et al., 1997; Hay et al., 2005). Yet, in 
functional assays, CGRP and amylin have similar potencies for the stimulation of cAMP 
production (Zimmermann et al., 1997; Ellegaard et al., 2010). This suggests that these cells 
may contain functional AMY1 and/or CGRP receptors. Curiously in direct contradiction to this, 
125I-CGRP was reported not to bind to MCF-7 cells under the conditions used suggesting that 
neither AMY1 nor CGRP receptors were present (Zimmermann et al., 1997). It is not clear 
whether CLR is expressed by MCF-7 cells. MCF-7 cells highlight the difficulties involved in 
the study of this family of heterodimeric receptors where cells may express multiple 
interchangeable receptor components. Overall, MCF-7 cells likely contain a mixture of 
receptors and therefore are not recommended as a model system for this peptide family. 
 
6. Receptor signalling 
6.1. Biased signalling 
Whilst it has been recognised for many years that CLR and CTR-based receptors signal through 
a variety of pathways, most work focussed on cAMP. Recently, work has started both to 
document the extent of signal bias and also to understand underlying mechanisms. 
 
In transfected HEK293 cells, a significant Gi-component was observed to the response to AM 
at CGRP receptors and to CGRP at AM1 and AM2 receptors; this Gi-component was not seen 
with CGRP or AM acting at their cognate receptors. The Gi component was not seen in 
HEK293S cells, perhaps reflecting low expression of this G protein. The results are broadly 
consistent with data obtained in Saccharomyces cerevisiae engineered to express versions of 
Gs and Gi, where AM is more potent than CGRP acting through the CGRP receptor and CGRP 
is more potent than AM at the AM1 receptor when measuring coupling to the Gi construct 
(Weston et al., 2016). Taken at face value, these results suggest that ligand bias can 
significantly change receptor selectivity. Caution is needed; the results have only been shown 
in a single, transfected, cell line; it remains to be established whether the effects are seen in 
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native cells. None-the-less, the data indicate the potential importance of biased signalling. This 
conclusion is reinforced by the pathway-selective antagonism previously discussed for 
olcegepant (Walker et al., 2017). In this study strong cell-dependent differences were seen in 
signalling with respect to ERK and p38. In rat trigeminal ganglion neuron cultures (which 
probably express both AMY1 and CGRP receptors), rat CGRP stimulated cAMP, CREB and 
p38 phosphorylation but not ERK. In Cos 7 cells transfected with human CGRP and AMY1(a) 
receptors, human CGRP stimulated cAMP, CREB and ERK phosphorylation, but not p38.  
 
There are processes such as stimulation of angiogenesis where cAMP-mediated mechanisms 
may be expected to be of minor importance compared to stimulation of pathways such as Akt 
(Nikitenko et al., 2006; Walker et al., 2010) and so biased agonists might be particularly useful, 
either to avoid or promote this effect. However, even here a contribution from cAMP is 
sometimes observed (Miyashita et al., 2003; Jin et al., 2008). There is a clear need to study 
signalling in physiologically relevant tissues and cells, to take into account all aspects of the 
inherent variability of receptor signalling. 
 
An important contribution to understanding the mechanism behind biased signalling has come 
from comparing the effects of human and salmon CT on G protein activation. Human CT has 
a higher efficacy of the two ligands. The two agonists stabilise forms of CTR which differ in 
their ability to interact with Gs (Furness et al., 2016). The molecular explanation for this 
observation remains to be established. 
 
6.2 Receptor internalisation and recycling 
In both transfected HEK cells and rat mesenteric smooth muscle cells, following challenge with 
CGRP, the ligand/CLR/RAMP1 complex is targeted to the early endosome. Cleavage of CGRP 
by endothelin-converting enzyme-1 within this organelle leads to the release of beta arrestins 
and recycling of the CLR/RAMP1 complex to the cell surface (McNeish et al., 2012). There 
may be significant cell and tissue variability in this response. Thus it has been reported that in 
human microvascular endothelial cells, AM but not CGRP could cause internalisation of both 
AM and CGRP receptors (Nikitenko et al., 2006). Curiously, there is a report that over-
expression of beta arrestin 1 or 2 both inhibit AM1 receptor internalisation in HEK cells 
(Kuwasako et al., 2017), although activation of GRKs 5 and 6 cause the expected 
internalisation (Kuwasako et al., 2016).  
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Internalisation of the CTR is well characterised. The internalisation rate differs between the 
hCT(a) and hCT(b), perhaps linked to the different signalling profiles of these splice variants 
(Moore et al., 1995). Interestingly it has been noted that the internalised CTR may continue to 
stimulate adenylate cyclase when stimulated by salmon but not human CT (Andreassen et al, 
2014b). The C-terminus of the CTR plays an important role in determining the fate of the 
internalised receptor; the rabbit CTR can bind to the actin-binding protein filamin and this 
promotes recycling (Seck et al., 2003); it is not known if this applies to other species as there 
are differences in the sequences of the C-terminus. In contrast, the fate and mechanisms of 
CTR trafficking in the presence of RAMPs is not known. 
 
It seems likely that internalisation of CLR- and CTR-based receptors depends on a combination 
of the cell line, the agonist, the splice variant (for CTR) and the RAMP, with both the C-
terminus (Bomberger et al., 2005a, Bomberger et al., 2005b) and the TMD (Kuwasako et al., 
2012) of the RAMP containing important determinants. The significance, if any, of signalling 
directed by internalised CTR or CLR complexes is unexplored. 
 
7. Unresolved questions, challenges and recommendations 
Since the identification that RAMPs are required for formation of AM, CGRP and amylin 
receptors great strides have been made in understanding their biology (McLatchie et al., 1998; 
Christopolous et al., 1999). However, the heterodimeric nature of these receptors results in 
unique challenges in understanding the pharmacological and physiological roles and several 
complications or questions have arisen in the field. 
 
1. Which amylin and AM receptors are biologically relevant? Although the combinations of 
CTR and RAMPs are described as amylin receptors, there is little protein data on the co-
expression of these subunits in tissues and it is not clear whether one or all of these ‘amylin 
receptors’ form functional complexes in vivo. To address this question highly specific probes 
(antibodies, labelled ligand and/or antagonists) for CTR alone and individual CTR/RAMP 
complexes are required. A very similar situation exists for AM, when it is extremely difficult 
to distinguish pharmacologically between AM1 and AM2 receptors. 
 
2. Amylin receptor studies may be complicated by co-expression with free CTR. CTR can reach 
the cell surface in the absence of a RAMP to form a receptor for CT or in the presence of a 
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RAMP to form an amylin receptor (Christopolous et al., 1999). The potential contribution of 
free CTR to the pharmacological profiles of amylin receptors in transfected cell models was 
discussed earlier in this review. Whether free CTR reaches the cell surface in the presence of 
RAMPs in vivo is not clear. It is possible that amylin receptors are commonly co-expressed 
with variable amounts of free CTR, complicating interpretation. 
 
3. Is the AMY1 receptor responsible for physiological actions of CGRP? Although the actions 
of CGRP are often assumed to be via the CGRP receptor in many cases a mixture of receptors 
may be involved or the receptor has simply not been identified. Given the high potency CGRP 
displays at the AMY1 receptor and the widespread distribution of components for the AMY1 
receptor in the nervous system and peripheral tissues it would be surprising if CGRP did not 
act endogenously at the AMY1 receptor (McLatchie et al., 1998; Oliver et al., 2001; Tolcos et 
al., 2003). This requires clarification. 
 
4. AM2/IMD has two different names and has activity at several receptors. AM2 or IMD was 
initially described by two different research groups (Roh et al., 2004, Takei et al., 2004). No 
consensus has been reached regarding a single name for this peptide and it is now generally 
referred to by both names as AM2/IMD (Hong et al., 2012). It is important to note that 
intermedin is an alternative name for melanocyte-stimulating hormone and was also used to 
describe plant compounds (Li et al., 2008). The dual name for AM2/IMD may cause confusion, 
especially for those unfamiliar with the field. Given that IMD does not exclusively describe 
the AM relative, we recommend the use of AM2 or AM2/IMD but never just IMD. It is also 
important that when referring to the CLR/RAMP3 receptor complex, a subscript 2 character is 
used i.e. AM2 receptor to clearly identify descriptions of the AM2 peptide and AM2 receptor. 
It is likely that existing complexes of CLR and/or CTR with RAMPs can explain AM2/IMD 
actions without needing to invoke alternative receptors. Better antagonists are needed and an 
awareness of differences in pharmacology between species should be acknowledged. 
 
5. βCGRP has widespread expression. βCGRP is often described as being predominantly 
expressed in the enteric nervous system. However, it is more correct to state that βCGRP is the 
predominant form of CGRP expressed in the enteric nervous system (Schutz et al., 2004). 
αCGRP and βCGRP are reportedly expressed throughout the nervous system with variable and 
overlapping distributions (Amara et al., 1985, Schutz et al., 2004). For example, αCGRP and 
βCGRP are both expressed in the dorsal root ganglia and dorsal horn of the spinal cord, whereas 
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αCGRP appears to be the predominant form expressed in the ventral horn of the spinal cord 
and at the neuromuscular junction (Schutz et al., 2004). Hence βCGRP should not be ignored 
as a widespread ligand for CGRP receptors. 
 
8. Conclusions 
The pharmacological classification of receptors for the CT/CGRP family as first proposed by 
NC-IUPHAR in 2002 remains a useful framework. There are however a number of conceptual 
challenges, many of which are highlighted in the previous section. Perhaps the most significant 
of these is that receptors of the AMY1 type may be activated physiologically by CGRP. There 
is also a lack of agents that can discriminate between AM1 and AM2 receptors, or any of the 
AMY receptors. This represents a major barrier to our understanding of the in vivo role of these 
subtypes. Whilst it is likely that coupling to Gs and cAMP is the main transduction pathway 
for receptors of this family, a much better exploration of ligand bias is needed. The 
development of new pharmacological agents will be facilitated by our increased molecular 
understanding of the receptors within this family, drawing on insights from both structural and 
computational biology. As these become available, our understanding of the physiology of 
these peptides and their potential therapeutic uses will increase. 
 
Nomenclature of targets and ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
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Table 1 Summary of structures of the of CTR and CLR/RAMP complexes with bound ligands. 
RAMP GPCR ligand RSCB PDB ID/ 
Reference 
Comment 
RAMP126-117 CLR22-133 Telcagepant 3N7R, (ter Haar et al., 
2010)  
 
RAMP126-117 CLR22-133 Olcegepant 3N7S, (ter Haar et al., 
2010) 
 
MBP-RAMP124-111-(GSA)3-CLR29-144-(H)6 CGRP27-37 
[D31,P34,F35] 
4RWG, (Booe et al., 
2015) 
CGRP has beta I-turn, with terminal F 
facing W84 of RAMP1 (Fig 7) 
MBP-RAMP2[L106R]55-140-(GSA)3-
CLR29-144-(H)6 
AM25-52 4RWF, (Booe et al., 
2015) 
AM has beta I-turn, with terminal Y facing 
E101 of RAMP2 (Fig 7) 
- H6-CTR25-144 [BrPhe
22]sCT8–32 5II0, (Johansson et al., 
2016) 
CT has beta II-turn, with terminal P facing 
W79/Y131 of CTR (Fig 7). 
- CTR with Gs and 
stabilising nanobody 
35 
sCT 5UZ7, (Liang et al., 
2017) 
Cryo-em structure. The ECD and ligand are 
not resolved. 
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Figure 1. Amino acid sequence alignments of the CT peptide family. In all peptides, a 
disulphide bond is formed between the two N-terminal cysteines and they each have a C-
terminal amide. For pCRSP1 this would occur on Phe37, presuming that the glycine is removed 
during processing like the other peptides. A) The human CT peptide family, omitting the N-
terminal extensions of AM and AM2. B) Alignment of full-length human AM and AM2. C) 
Sequence alignment of human α and βCGRP, rat α and βCGRP and pig αCGRP and CRSP1. 
h-human, r-rat, p-pig. Alignment performed in COBALT 
(https://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?CMD=Web) and analysed using 
BoxShade (http://ch.embnet.org/software/BOX_form.html). Black indicates exact match, grey 
indicates 70-100% similarity and white indicates <70% similarity. 
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Figure 2. The subunit composition and current classification of human calcitonin-family 
receptors. The legend is shown in the box. Ligands are indicated by spheres with relative sizes 
reflecting relative potency at each receptor, with the smaller sphere indicating lower potency 
of a given ligand. 
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Figure 3. The pharmacology of selected ligands across CGRP, AM1 and AM2 receptors. 
All receptors are human and data are pEC50 values for cAMP production in cells transfected to 
express receptors. Each point is an individual value from independent publications, except 
where different cell lines were used within a single study and two values are therefore used 
from that study. The individual values and references can be found in Supplementary Data. 
The mean pEC50 is shown; error bars represent S.E.M. The CGRP receptor (CLR/RAMP1) is 
brown, AM1 receptor (CLR/RAMP2) is red, AM2 receptor (CLR/RAMP3) is purple. For 
ligands, αCGRP is a filled circle, CGRP in an open square, AM is a filled square, AM2/IMD 
is an open circle.  
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Figure 4. The binding of and cAMP production by rat amylin (rAmy) and human CT 
(hCT) in AMY1(a) and AMY3(a) transfected Cos7 cells. A) Displacement of I125-amylin by 
amylin and CT at the AMY1(a) receptor. B) Displacement of I
125-amylin by amylin and CT at 
the AMY3(a) receptor. C) cAMP responses to amylin and CT at the AMY1(a) receptor. D) cAMP 
responses to amylin and CT at the AMY3(a) receptor. Data replotted from Hay et al., 2005. 
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Figure 5. The pharmacology of A) the AMY1(a) receptor and B) CGRP across various 
receptors. All receptors are human and data are pEC50 values for cAMP production in cells 
transfected to express receptors. Each point is an individual value from independent 
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publications, except where different cell lines were used within a single study and two values 
are therefore used from that study. The individual values and references can be found in 
Supplementary Data. The mean pEC50 is shown; error bars represent S.E.M. The CGRP 
receptor (CLR/RAMP1) is brown, AM1 receptor (CLR/RAMP2) is red, AM2 receptor 
(CLR/RAMP3) is purple, CTR is green, the AMY1 receptor (CTR/RAMP1) is blue, AMY2 
receptor (CTR/RAMP2) is orange, and AMY3 receptor is pink. For ligands, αCGRP is a filled 
circle, rat amylin (rAmy) is a filled triangle, human amylin (hAmy) is an open triangle and 
CGRP is an open square. Data were analysed by one-way ANOVA followed by Tukey’s test; 
in B) only the key comparison is shown. 
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Figure 6. Relative distribution of the mRNA for AM and AM2/IMD. The data was taken 
from the HPA RNA-seq normal tissues database, available via the NCBI Gene website 
https://www.ncbi.nlm.nih.gov/gene). Values were normalised to 100% for the highest 
expressing tissue for both peptides. Similar expression profiles can be seen at 
http://www.proteinatlas.org/ENSG00000148926-ADM/tissue and 
http://www.proteinatlas.org/ENSG00000128165-ADM2/tissue.   
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Figure 7. The pharmacology AM and AM2/IMD at CGRP, AM1 and AM2 receptors. All 
receptors are human and data are pEC50 values for cAMP production in cells transfected to 
express receptors. Each point is an individual value from independent publications, except 
where different cell lines were used within a single study and two values are therefore used 
from that study. The individual values and references can be found in Supplementary Data. 
The mean pEC50 is shown; error bars represent S.E.M. The CGRP receptor (CLR/RAMP1) is 
brown, AM1 receptor (CLR/RAMP2) is red, AM2 receptor (CLR/RAMP3) is purple. AM is a 
filled square, AM2/IMD is an open circle. Data were analysed by one-way ANOVA followed 
by Tukey’s test; *p<0.05.  
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Figure 8. Structural alignment of CTR and CLR based receptor ECDs with bound 
ligands. A) Far and B) near views of the CTR and CLR/RAMP1 ECDs bound to 
[BrPhe22]sCT8-32 or [D
31,P34,F35]hαCGRP27-37, respectively. C) Far and D) near views of the 
CLR/RAMP1 and CLR/RAMP2 ECDs bound to [D31,P34,F35]hαCGRP27-37 or hAM22-52, 
respectively. All receptor ECDs are human. The C-terminal residue of each peptide is shown 
in stick format and the RAMP residue important for peptide interactions (RAMP1 
W84/RAMP2 E101) shown in line format. Images created in pymol and aligned based on 
similarities between CTR and CLR or CLR and CLR. Images rotated 90° in the Z-plane 
between near and far views 
 
 
